 HAUPPAUGE, N.Y., Aug. 27, 2021 GLOBE NEWSWIRE -- Chembio Diagnostics, Inc. Nasdaq: CEMI, a leading point-of-care diagnostics company focused on infectious diseases, today announced its launch of commercial distribution of an FDA Emergency Use Authorized, patent pending, rapid point-of-care COVID-19 antigen test for use in decentralized and traditional testing settings. Product inventory is on-hand and immediately available for shipment to Chembio customers across the United States. 